Treatment of clostridium difficile infection
Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.
1. A pharmaceutical composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO:20, and SEQ ID NO:21; and one or more enteric polymers; wherein the pharmaceutical composition comprises between 1×10 7 and 1×10 10 colony forming units (CFUs) per bacterial strain; and wherein the pharmaceutical composition is in the form of a capsule.
2. The pharmaceutical composition of claim 1 , wherein one or more of the bacterial strains are spore-formers.
3. The pharmaceutical composition of claim 1 , wherein the bacterial strains originate from more than one human donor.
4. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the colon.